HINT3 suppresses AKT/mTOR signaling pathway activity during breast cancer tumorigenesis through PTEN transcriptional activation

被引:3
作者
Li, Jinping [1 ]
Liu, Yaobang [1 ]
Lian, Bing [1 ]
Li, Hong [1 ]
Chai, Dahai [1 ]
Gao, Yali [1 ]
Wang, Yanbai [1 ]
机构
[1] Ningxia Med Univ, Dept Surg Oncol, Gen Hosp, 804 Shengli South St, Yinchuan 750004, Ningxia, Peoples R China
基金
中国国家自然科学基金;
关键词
histidine triad nucleotide-binding protein 3; breast cancer; proliferation; migration; phosphatase and tensin homolog; AKT; TUMOR-SUPPRESSOR; GENE-EXPRESSION; MECHANISM; BRCA1;
D O I
10.3892/ijmm.2023.5257
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Histidine triad nucleotide-binding protein (HINT) belongs to the histidine triad protein family. Recent studies have demonstrated that HINT1 and HINT2 both play a pivotal role in cancer growth. However, the functions of HINT3 in various types of cancer, including breast cancer (BRCA), have not yet been fully elucidated. In the present study, the role of HINT3 in BRCA was investigated. Based on The Cancer Genome Atlas and reverse transcription-quantitative PCR analyses, HINT3 was found to be decreased in BRCA tissues. In vitro, HINT3 knockdown promoted the proliferation and colony formation of, and 5-ethynyl-2 '-deoxyuridine incorporation in MCF-7 and MDA-MB-231 BRCA cells. By contrast, HINT3 overexpression suppressed DNA synthesis and the proliferation of both cell lines. Apoptosis was also found to be modulated by HINT3. In vivo, HINT3 ectopic expression attenuated the tumorigenesis of MDA-MB-231 and MCF-7 cells in a mouse tumor xenograft model. Furthermore, HINT3 silencing or overexpression also enhanced or inhibited, respectively, the migratory capacity of the MCF-7 and MDA-MB-231 cells. Finally, HINT3 upregulated phosphatase and tensin homolog (PTEN) at the transcriptional level, which resulted in the inactivation of AKT/mammalian target of rapamycin (mTOR) signaling both in vitro and in vivo. Taken together, the present study demonstrates that HINT3 inhibits the activation of the PTEN/AKT/mTOR signaling pathway, and suppresses the proliferation, growth, migration and tumor development of MCF-7 and MDA-MB-231 BRCA cells.
引用
收藏
页数:13
相关论文
共 39 条
[1]   Development of Resistance towards Artesunate in MDA-MB-231 Human Breast Cancer Cells [J].
Bachmeier, Beatrice ;
Fichtner, Iduna ;
Killian, Peter H. ;
Kronski, Emanuel ;
Pfeffer, Ulrich ;
Efferth, Thomas .
PLOS ONE, 2011, 6 (05)
[2]   BRCA in breast cancer: ESMO Clinical Practice Guidelines [J].
Balmana, J. ;
Diez, O. ;
Rubio, I. T. ;
Cardoso, F. .
ANNALS OF ONCOLOGY, 2011, 22 :vi31-vi34
[3]   The PI3K/Akt/mTOR pathway: A potential pharmacological target in COVID-19 [J].
Basile, Maria Sofia ;
Cavalli, Eugenio ;
McCubrey, James ;
Hernandez-Bello, Jorge ;
Munoz-Valle, Jose Francisco ;
Fagone, Paolo ;
Nicoletti, Ferdinando .
DRUG DISCOVERY TODAY, 2022, 27 (03) :848-856
[4]  
Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI [10.3322/caac.21609, 10.3322/caac.21492]
[6]   UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses [J].
Chandrashekar, Darshan S. ;
Bashel, Bhuwan ;
Balasubramanya, Sai Akshaya Hodigere ;
Creighton, Chad J. ;
Ponce-Rodriguez, Israel ;
Chakravarthi, Balabhadrapatruni V. S. K. ;
Varambally, Sooryanarayana .
NEOPLASIA, 2017, 19 (08) :649-658
[7]   Evidence that human histidine triad nucleotide binding protein 3 (Hint3) is a distinct branch of the histidine triad (HIT) superfamily [J].
Chou, Tsui-Fen ;
Cheng, Jilin ;
Tikh, Ilya B. ;
Wagner, Carston R. .
JOURNAL OF MOLECULAR BIOLOGY, 2007, 373 (04) :978-989
[8]   PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast Cancer [J].
Costa, Carlotta ;
Wang, Ye ;
Ly, Amy ;
Hosono, Yasuyuki ;
Murchie, Ellen ;
Walmsley, Charlotte S. ;
Huynh, Tiffany ;
Healy, Christopher ;
Peterson, Rachel ;
Yanase, Shogo ;
Jakubik, Charles T. ;
Henderson, Laura E. ;
Damon, Leah J. ;
Timonina, Daria ;
Sanidas, Ioannis ;
Pinto, Christopher J. ;
Mino-Kenudson, Mari ;
Stone, James R. ;
Dyson, Nicholas J. ;
Ellisen, Leif W. ;
Bardia, Aditya ;
Ebi, Hiromichi ;
Benes, Cyril H. ;
Engelman, Jeffrey A. ;
Juric, Dejan .
CANCER DISCOVERY, 2020, 10 (01) :72-85
[9]   Potential use of rapamycin in HIV infection [J].
Donia, Marco ;
McCubrey, James A. ;
Bendtzen, Klaus ;
Nicoletti, Ferdinando .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 70 (06) :784-793
[10]   Everolimus inhibits breast cancer cell growth through PI3K/AKT/mTOR signaling pathway [J].
Du, Liyan ;
Li, Xiaomei ;
Zhen, Linhong ;
Chen, Weiling ;
Mu, Lingguang ;
Zhang, Yang ;
Song, Ailin .
MOLECULAR MEDICINE REPORTS, 2018, 17 (05) :7163-7169